Watch LPCN. Know when insiders buy.
One email the day a filing lands. Free.
LPCN
Lipocine Inc.
2.21
−0.01 −0.45%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · shorts 34
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $18.2MP/E —DIV YIELD —FCF YIELD —REV TTM $1.6M −62.7%NET INCOME −$11.9MNET CASH $4.1M52W 1.94 – 11.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $190K | −69.5% | — | −$2.8M | −$2.6M | — | -0.32 | −$3M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $119K | +27.2% | — | −$3.8M | −$3.7M | — | -0.54 | −$2.3M | — | — | May 7 |
| Q4 2025 · Dec 31derived | $1.1M | −67.2% | — | −$2.5M | −$2.4M | −233.0% | -0.34 | −$2.9M | — | — | Mar 10 |
| Q3 2025 · Sep 30 | $115K | — | — | −$3.4M | −$3.2M | — | -0.59 | −$3M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $623K | +595.4% | — | −$2.4M | −$2.2M | — | -0.41 | −$1.9M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $94K | −98.8% | — | −$2.1M | −$1.9M | −153.1% | -0.35 | −$2M | — | — | May 7 |
| Q4 2024 · Dec 31derived | $3.5M | +1515.0% | — | $1.5M | $1.8M | — | — | $1.7M | $10K | $1.7M | Mar 10 |
| Q3 2024 · Sep 30 | $0 | — | — | −$2.6M | −$2.2M | — | -0.44 | −$2.8M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $90K | — | — | −$3.3M | −$3.1M | — | -0.56 | −$2.5M | — | — | Aug 5 |
| Q1 2024 · Mar 31 | $7.6M | — | — | $3.2M | $3.5M | — | 0.66 | $2.4M | — | — | May 8 |
| Q4 2023 · Dec 31derived | $216K | — | — | −$2.6M | −$2.3M | — | -0.42 | −$2M | $9K | −$2M | Mar 13 |
| Q3 2023 · Sep 30 | −$3.1M | — | — | −$7M | −$6.7M | — | -1.27 | −$2.6M | $0 | −$2.6M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2M | — | −$10.4M | −$9.6M | -487.1% | -1.69 | −$9.8M | — | — | — | — |
| FY2024 · to Dec 31 | $11.2M | — | −$1.2M | $8K | 0.1% | — | −$1.2M | $90K | −$1.3M | — | — |
| FY2023 · to Dec 31 | −$2.9M | — | −$17.9M | −$16.4M | 573.6% | -3.14 | −$11.9M | $13K | −$11.9M | — | — |
| FY2022 · to Dec 31 | $500K | — | −$12.1M | −$10.8M | -2151.7% | -2.15 | −$12M | $134K | −$12.1M | — | — |
| FY2021 · to Dec 31 | $16.1M | — | $3.1M | −$634K | -3.9% | -0.01 | −$4.4M | $8K | −$4.4M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$18M | −$21M | — | -0.38 | −$15.3M | — | — | — | — |
Every number comes from Lipocine Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.